CYT 150
Alternative Names: CYT-150Latest Information Update: 11 Nov 2022
At a glance
- Originator Cytovia Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Liver cancer; Solid tumours
- Discontinued Haematological malignancies
Most Recent Events
- 11 Nov 2022 Cytovia intends to submit IND application for CYT 150 and CYT 303 in Liver cancer in 2024 (Cytovia Therapeutics pipeline, November 2022)
- 11 Nov 2022 Cytovia announces intention to submit IND for liver cancer and other tumour in 2024 (Cytovia Therapeutics pipeline, November 2024)
- 27 Apr 2022 Cytovia Therapeutics plans phase I/II trials